Mauna Kea Technologies to Present at the American Gastroenterological Association’s 2012 Fostering Innovation and Technology in Digestive and Metabolic Diseases Conference

PARIS--(Marketwire - March 23, 2012) - Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), the leader in the endomicroscopy market, announced today that Sacha Loiseau, PhD, founder and Chief Executive Officer, will present at the American Gastroenterological Association’s (AGA) annual technology conference focused on “Fostering Innovation and Technology in Digestive and Metabolic Diseases.”

Loiseau will provide an overview of the company’s flagship Cellvizio® probe-based confocal laser endomicroscopy (pCLE) system and the clinical and business milestones that led to the company’s $70 million initial public offering on the NYSE Euronext exchange in July 2011. Loiseau will offer advice to private, GI-focused medical device companies weighing exit strategies, including decisions to go public in the U.S. or abroad.

Cellvizio, the world’s smallest microscope, is the first system designed to provide live cellular-level images of internal human tissues during endoscopic procedures. Gastroenterologists across the U.S., Europe and Asia use the system to gain more information about their patients’ GI and biliary conditions so they can make more informed treatment decisions at the bedside.

The conference runs from March 23 to 24 at the Four Seasons Hotel Silicon Valley in East Palo Alto, CA.

The AGA’s Fostering Innovation in Digestive and Metabolic Diseases conference brings together medical device companies, reimbursement experts/consultants, policymakers, investors, inventors, physician innovators and key opinion leaders to examine the issues surrounding the development and delivery of new technologies to the GI market.

The program will identify unmet needs in GI as well as highlight new promising technologies, delivering vital information on what it takes to obtain approval, adoption, coverage and reimbursement in today’s healthcare environment. Industry and regulatory experts will field questions from the audience through moderated panel discussions, allowing for engaging and open dialogue about the challenges presented by current requirements and how to best address these challenges.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio’s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Mauna Kea Technologies (“the Company”) in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marches financiers (“AMF”) granted its visa number 11-236 on June 20, 2011, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.